IN THE NEWS
Mayne Pharma Announces Strategic investment in US Facilities
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals. Mayne Pharma provides contract development and manufacturing services to more than 100 clients worldwide...
Mayne Pharma has enhanced its generic products portfolio with 42 products acquired from Teva/Allergan. We now offer branded and generic drugs for a range of therapeutic areas, including oral contraception, oncology, dermatology and cardiology, in an array of dosage forms...
NEWS AND EVENTS
Mayne Pharma 2016 Results Media Release 2016 Full Year Results (Click here to register for the webcast on 26th August 2016 at 10.00am AEST) Mayne Pharma announces acquisition of US foam dermatology assets Acquisition of US generic product portfolio from Teva and Allergan MYX receives first generic approval of Tikosyn capsules
One of the keys to Mayne Pharma’s success has been the implementation of strategic partnerships and alliances by licensing products that we are able to market in the USA or Australia and to develop partnerships for the global marketing of products developed by Mayne Pharma...
Mayne Pharma has a 30-year track record of innovation and success developing new oral drug delivery systems and these technologies have been successfully commercialized in numerous products that have been marketed around the world...
|Market Cap:||52 Week: -|